Literature DB >> 10469139

Down-regulation of endothelial cell growth inhibitors by enhanced MYCN oncogene expression in human neuroblastoma cells.

T Fotsis1, S Breit, W Lutz, J Rössler, E Hatzi, M Schwab, L Schweigerer.   

Abstract

Recent evidence indicates that the genetic alterations of the multistage process of malignant transformation appear to activate tumor neovascularization by altering the balance between stimulators and inhibitors of angiogenesis. In the present study, we have attempted to define the effect of enhanced MYCN oncogene expression on the profile of endothelial cell growth modulators in neuroblastoma cells. We report here that conditioned medium of human neuroblastoma cells with normal MYCN expression contains three inhibitors of endothelial cell proliferation, which appear to be novel proteins as judged by their physicochemical, immunological and biological properties. All three inhibitors are diminished or become undetectable upon experimental increase of MYCN expression. Our results suggest that enhanced MYCN expression in human neuroblastoma cells alters the angiogenic balance by down-regulating endothelial cell growth inhibitors but leaving the expression of the stimulators unaffected. These data shed light on the molecular mechanisms linking the genetic changes of malignant transformation with initiation of tumor angiogenesis. Moreover, our observations might explain the poor prognosis of human neuroblastomas following MYCN oncogene amplification through initiation of angiogenesis and subsequent tumor growth and spread.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10469139     DOI: 10.1046/j.1432-1327.1999.00575.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  13 in total

Review 1.  Angiogenic molecules and mechanisms in breast cancer.

Authors:  I Wu; M A Moses
Journal:  Curr Oncol Rep       Date:  2000-11       Impact factor: 5.075

2.  The Myc-dependent angiogenic switch in tumors is mediated by interleukin 1beta.

Authors:  Ksenya Shchors; Elena Shchors; Fanya Rostker; Elizabeth R Lawlor; Lamorna Brown-Swigart; Gerard I Evan
Journal:  Genes Dev       Date:  2006-09-15       Impact factor: 11.361

3.  Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts.

Authors:  Thorsten Berg; Steven B Cohen; Joel Desharnais; Corinna Sonderegger; Daniel J Maslyar; Joel Goldberg; Dale L Boger; Peter K Vogt
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-12       Impact factor: 11.205

4.  The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma.

Authors:  Andrew Slack; Zaowen Chen; Roberto Tonelli; Martin Pule; Lisa Hunt; Andrea Pession; Jason M Shohet
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-11       Impact factor: 11.205

5.  The Many Faces of MDM2 Binding Partners.

Authors:  Maurisa F Riley; Guillermina Lozano
Journal:  Genes Cancer       Date:  2012-03

6.  N-myc is a novel regulator of PI3K-mediated VEGF expression in neuroblastoma.

Authors:  J Kang; P G Rychahou; T A Ishola; J M Mourot; B M Evers; D H Chung
Journal:  Oncogene       Date:  2008-02-18       Impact factor: 9.867

7.  Metabolic characteristics of 13-cis-retinoic acid (isotretinoin) and anti-tumour activity of the 13-cis-retinoic acid metabolite 4-oxo-13-cis-retinoic acid in neuroblastoma.

Authors:  Poonam Sonawane; Hwang Eui Cho; Ashujit Tagde; Dattesh Verlekar; Alice L Yu; C Patrick Reynolds; Min H Kang
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

Review 8.  Neuroblastoma and MYCN.

Authors:  Miller Huang; William A Weiss
Journal:  Cold Spring Harb Perspect Med       Date:  2013-10-01       Impact factor: 6.915

Review 9.  Targeting ALK in neuroblastoma--preclinical and clinical advancements.

Authors:  Erica L Carpenter; Yael P Mossé
Journal:  Nat Rev Clin Oncol       Date:  2012-05-15       Impact factor: 66.675

10.  Targeting metabolic activity in high-risk neuroblastoma through Monocarboxylate Transporter 1 (MCT1) inhibition.

Authors:  Aaminah Khan; Emanuele Valli; Hayley Lam; David A Scott; Jayne Murray; Kimberley M Hanssen; Georgina Eden; Laura D Gamble; Rupinder Pandher; Claudia L Flemming; Sophie Allan; Andrei L Osterman; Michelle Haber; Murray D Norris; Jamie I Fletcher; Denise M T Yu
Journal:  Oncogene       Date:  2020-03-02       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.